Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 14:14:1150055.
doi: 10.3389/fphar.2023.1150055. eCollection 2023.

Editorial: Pharmaceutical policy, impact and health outcomes

Hye-Young Kwon  1 , Brian Godman  2   3   4
Affiliations
Editorial

Editorial: Pharmaceutical policy, impact and health outcomes

Hye-Young Kwon et al. Front Pharmacol. .
No abstract available

Keywords: cancer; cost-effectiveness; health outcomes; impact; non-communicable diseases; pharmaceutical policy; polypharmacy; procurement policies.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Pharmaceutical policy, impact and health outcomes

References

    1. Acosta A., Vanegas E. P., Rovira J., Godman B., Bochenek T. (2019). Medicine shortages: Gaps between countries and global perspectives. Front. Pharmacol. 10, 763. 10.3389/fphar.2019.00763 - DOI - PMC - PubMed
    1. Al-Ziftawi N. H., Shafie A. A., Mohamed Ibrahim M. I. (2021). Cost-effectiveness analyses of breast cancer medications use in developing countries: A systematic review. Expert Rev. Pharmacoecon Outcomes Res. 21 (4), 655–666. 10.1080/14737167.2020.1794826 - DOI - PubMed
    1. Ali M. H., Alrasheedy A. A., Kibuule D., Godman B., Hassali M. A., Ali H. M. H. (2019). Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Rev. Anti Infect. Ther. 17 (11), 927–937. 10.1080/14787210.2019.1689818 - DOI - PubMed
    1. Barbosa M. M., Moreira T. A., Nascimento R. C., Nascimento M. M., Acurcio F. A., Godman B., et al. (2021). Access to medicines in the Brazilian unified health system's primary health care: Assessment of a public policy. J. Comp. Eff. Res. 10 (10), 869–879. 10.2217/cer-2021-0026 - DOI - PubMed
    1. Baumgart D. C., Misery L., Naeyaert S., Taylor P. C. (2019). Biological therapies in immune-mediated inflammatory diseases: Can biosimilars reduce access inequities? Front. Pharmacol. 10, 279. 10.3389/fphar.2019.00279 - DOI - PMC - PubMed

Publication types

LinkOut - more resources